12-24 Hours
Safety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Imuran 50. Please consult your doctor.
CONSULT YOUR DOCTOR
Imuran 50 is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
CONSULT YOUR DOCTOR
Imuran 50 is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
CONSULT YOUR DOCTOR
It is not known whether Imuran 50 alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
CAUTION
Imuran 50 should be used with caution in patients with kidney disease. Dose adjustment of Imuran 50 may be needed. Please consult your doctor.
Use of Imuran 50 is not recommended in patients with serious kidney disease.
CAUTION
Imuran 50 should be used with caution in patients with liver disease. Dose adjustment of Imuran 50 may be needed. Please consult your doctor.
Use of Imuran 50 is not recommended in patients with severe liver disease. Regular monitoring of liver function tests is advisable while you are taking this medicine.
Medicine Overview of Imuran 50mg tablet
Introduction
Imuran 50 belongs to a group of medicines called immunosuppressants. It is used with other medicines to prevent your body rejecting an organ (such as a kidney, heart or liver) after a transplant. It works by weakening your body’s immune system, so it does not attack the new organ. The amount of Imuran 50 to be taken and how often you need to take it will depend on the type of transplant you have. Follow your doctor's instructions on this. You should take it along with food. Swallow it as a whole, do not crush, chew, break, or open them....
... Show moreUses of Imuran 50
- Prevention of organ rejection in transplant patients
- Rheumatoid arthritis
Side effects of Imuran 50
Common
- Decreased white blood cell count
- Increased bleeding tendency
- Nausea
- Infection
- Loss of appetite
How to use Imuran 50
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Imuran 50 is to be taken with food.
How Imuran 50 works
Imuran 50 is an immunosuppressant. It reduces the action of body's own defense system (the immune system) and prevents rejection of the transplanted organ. It also blocks the action of certain chemical messengers that are responsible for inflammation, swelling, and redness associated with certain joint diseases.
Quick Tips
- Your doctor has prescribed Imuran 50 to stop the body from rejecting a transplanted organ (e.g. kidney, heart or liver).
- Imuran 50 also relieves joint pain and inflammation in rheumatoid arthritis.
- You may have to take additional medications along with Imuran 50 for better relief of symptoms.
- Avoid contact with people who have cold, flu or other contagious illness. Notify your doctor if you have any signs of infection such as a fever or sore throat.
- Inform your doctor if you are pregnant or planning to conceive or breastfeeding.
Brief Description
Indication
Rheumatoid arthritis, Prevention of rejection in organ and tissue transplantation, Auto-immune diseases, Renal homotransplantation
Administration
May be taken with or without food. Preferably taken w/ or after meals to reduce GI discomfort.
Adult Dose
Rheumatoid Arthritis
1 mg/kg/day PO initially in single daily dose or divided q12hr; may be increased by 0.5 mg/kg/day after 6-8 weeks, then by 0.5 mg/kg/day every 4 weeks; not to exceed 2.5 mg/kg/day
Maintenance: Reduce daily dose by 0.5 mg/kg every 4 weeks until lowest effective dosage is reached
Kidney Transplantation
Prevention of transplant rejection
3-5 mg/kg/day PO initially on day of transplant or 3 days before transplant (rare)
Maintenance: 1-3 mg/kg/day PO
Auto-immune diseases 1-3 mg/kg/day.
Hepatic Impairment Reduce dose.
Child Dose
Juvenile Idiopathic Arthritis
1 mg/kg/day PO initially in single daily dose or divided q12hr; may be increased by 0.5 mg/kg/day after 6-8 weeks, then by 0.5 mg/kg/day every 4 weeks; not to exceed 2.5 mg/kg/day
Maintenance: Reduce daily dose by 0.5 mg/kg every 4 weeks until lowest effective dosage is reached
Renal Dose
Reduce dose.
Contraindication
Hypersensitivity; previous treatment with alkylating agents; pregnancy, lactation.
Mode of Action
Azathioprine is an imidazolyl derivative of mercaptopurine, which inhibits DNA, RNA and protein synthesis and antagonises purine synthesis. It also inhibits mitosis and interferes with cellular metabolism of susceptible organisms. Azathioprine inj should be converted to oral therapy as soon as the drug can be tolerated.
Precaution
Increased risk of serious infections and neoplasia in chronic immunosuppression; leucopenia, thrombocytopenia, renal or hepatic impairment. Increased risk of haematologic toxicity in patients with thiopurine methyltransferase deficiency. Monitor CBC (including platelet count) wkly during 1st mth, twice mthly for 2nd and 3rd mth, then mthly; monitor more frequently if there are dosage adjustments. Monitor LFT periodically; discontinue treatment if jaundice occurs. Reduce dose promptly or withdraw drug temporary if there is rapid decrease/persistently low WBC or signs of bone marrow depression. Dose reduction may be necessary in patients with reduced TPMT (thiopurine methyltransferase) activity. Lactation: Drug excreted at low levels...
... Show moreSide Effect
>10%
Leukopenia (28-50%),Infection (20%)
<1%
Lymphoma
Frequency Not Defined
Fever, chills; bone marrow depression, thrombocytopenia or anaemia; anorexia, nausea, diarrhoea; arthralgias; secondary infections; hepatotoxicity, rash, alopoecia.
Potentially Fatal: Myelosuppression, mutagenicity and carcinogenicity; veno-occlussive liver disease.
Pregnancy Category Note
Pregnancy category: D
Lactation: Drug excreted at low levels in breast milk; use not recommended
Interaction
Increased risk of haematotoxicity with aminosalicylates, drugs that affect myelopoesis e.g. co-trimoxazole or trimethoprim. Increased risk of infections with intra-uterine devices and live vaccines. Increased risk of leucopenia with ACE inhibitors. Concurrent use may reduce the anticoagulant effect of vitamin K antagonists e.g. warfarin. Increased risk of myelosuppressive effects when used with drugs that inhibit TPMT (thiopurine methyltransferase) or xanthine oxidase e.g. olsalazine, allopurinol.
Potentially Fatal: Increased risk of serious haematotoxicity or hepatotoxicity with leflunomide. Increased risk of bone marrow suppression with mycophenolate mofetil. Increased risk of infections and malignancies with efalizumab.
